{"organizations": [], "uuid": "406d445144e67a1ff00fa8f7bb78a0a865a3a3bd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-abbott-posts-q4-adj-eps-074-from-c/brief-abbott-posts-q4-adj-eps-0-74-from-continuing-operations-idUSASB0C22W", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbott Posts Q4 Adj. EPS $0.74 From Continuing Operations", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.882, "site_type": "news", "published": "2018-01-24T20:58:00.000+02:00", "replies_count": 0, "uuid": "406d445144e67a1ff00fa8f7bb78a0a865a3a3bd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-abbott-posts-q4-adj-eps-074-from-c/brief-abbott-posts-q4-adj-eps-0-74-from-continuing-operations-idUSASB0C22W", "ord_in_thread": 0, "title": "BRIEF-Abbott Posts Q4 Adj. EPS $0.74 From Continuing Operations", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "abbott laboratories", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Abbott Laboratories:\n* ABBOTT REPORTS FOURTH-QUARTER 2017 RESULTS * SEES Q1 2018 ADJUSTED EARNINGS PER SHARE $0.57 TO $0.59 FROM CONTINUING OPERATIONS EXCLUDING ITEMS\n* SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.80 TO $2.90 FROM CONTINUING OPERATIONS\n* SEES Q1 2018 GAAP EARNINGS PER SHARE $0.16 TO $0.18 FROM CONTINUING OPERATIONS\n* SEES FY 2018 GAAP EARNINGS PER SHARE $1.22 TO $1.32 FROM CONTINUING OPERATIONS\n* Q4 ADJUSTED EARNINGS PER SHARE $0.74 FROM CONTINUING OPERATIONS\n* Q4 GAAP LOSS PER SHARE $0.50 FROM CONTINUING OPERATIONS * Q4 EARNINGS PER SHARE VIEW $0.73 -- THOMSON REUTERS I/B/E/S\n* ‍HAD NET EXPENSE OF $1.46 BILLION FOR ESTIMATED IMPACT OF TAX CUTS AND JOBS ACT​ IN QUARTER\n* QTRLY TOTAL PEDIATRIC SALES $1,000 MILLION, UP 2.4 PERCENT ON A REPORTED BASIS\n* FY2018 EARNINGS PER SHARE VIEW $2.83 -- THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $0.56 -- THOMSON REUTERS I/B/E/S\n* QTRLY TOTAL DIAGNOSTICS SALES $‍1,906​ MILLION, UP 51.7 PERCENT ON A REPORTED BASIS\n* QTRLY TOTAL VASCULAR SALES $734 MILLION, UP 17.2 PERCENT ON REPORTED BASIS\n* QTRLY TOTAL NUTRITION SALES $‍1,784​ MILLION, UP 3 PERCENT ON A REPORTED BASIS\n* FORECASTS NET SPECIFIED ITEMS FOR FULL YEAR 2018 OF APPROXIMATELY $1.58 PER SHARE\n* Q4 2017 WORLDWIDE SALES OF $7.6 BILLION INCREASED 42.3 PERCENT ON A REPORTED BASIS​\n* Q4 REVENUE VIEW $7.39 BILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T20:58:00.000+02:00", "crawled": "2018-01-25T13:22:17.056+02:00", "highlightTitle": ""}